Kidney cancer, also known as renal cell carcinoma, is a type of cancer that starts in the cells of the kidney. Metastatic kidney cancer occurs when the cancer has spread beyond the kidney to other parts of the body. Treatment options for metastatic kidney cancer typically involve surgery, targeted therapy, immunotherapy, and chemotherapy.
Two commonly used targeted therapies for the second-line treatment of metastatic kidney cancer are cabozantinib and axitinib. A recent study called the Action Kidney Cancer Study aimed to compare the effectiveness and safety of these two drugs in patients with metastatic kidney cancer.
Cabozantinib is a tyrosine kinase inhibitor that works by blocking the action of certain proteins involved in the growth and spread of cancer cells. Axitinib is also a tyrosine kinase inhibitor that targets similar proteins. Both drugs have been shown to be effective in slowing down the progression of metastatic kidney cancer and improving overall survival rates.
The Action Kidney Cancer Study enrolled over 500 patients with metastatic kidney cancer who had previously received one line of treatment. The patients were randomly assigned to receive either cabozantinib or axitinib as their second-line treatment. The study found that cabozantinib was associated with a longer progression-free survival compared to axitinib. Additionally, patients treated with cabozantinib had a higher overall response rate and a longer duration of response.
In terms of safety, both cabozantinib and axitinib were generally well-tolerated by patients. However, cabozantinib was associated with a higher incidence of certain side effects such as hypertension, diarrhea, and fatigue. On the other hand, axitinib was more likely to cause hand-foot syndrome, a condition characterized by redness, swelling, and pain on the palms of the hands and soles of the feet.
Overall, the results of the Action Kidney Cancer Study suggest that cabozantinib may be a more effective second-line treatment option for patients with metastatic kidney cancer compared to axitinib. However, the choice between these two drugs should be based on individual patient factors such as overall health, treatment goals, and tolerance to side effects.
It is important for patients with metastatic kidney cancer to discuss their treatment options with their healthcare provider to determine the most appropriate course of action. Ongoing research and clinical trials are continuously evaluating new therapies and combinations of treatments to improve outcomes for patients with metastatic kidney cancer.
- The Renal Warrior Project. Join Now
- Source: Plato Data Intelligence.
- Source: https://renal.platohealth.ai/comparison-of-cabozantinib-with-axitinib-as-second-line-treatment-for-metastatic-kidney-cancer-action-kidney-cancer/